2-Substituted Acetamidobenzamide Derivatives and Their Application in the Preparation of Anti-influenza Virus Drugs

A novel influenza virus inhibitor was developed by molecular docking a 2-substituted acetamidobenzamide derivative with influenza virus RNA polymerase, which solved the problem of drug resistance in existing anti-influenza drugs and achieved effective treatment of influenza virus.

CN117903056BActive Publication Date: 2026-11-10SHENYANG PHARMA UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410054235.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-15
Publication Date
2026-11-10
Estimated Expiration
2044-01-15

AI Technical Summary

Technical Problem

Existing anti-influenza drugs face the problem of drug resistance, making it urgent to find new targets to develop effective anti-influenza virus drugs. RNA-dependent RNA polymerase (RdRP) is a conserved and easily targeted target, and 2-substituted acetamidobenzamide derivatives are potential influenza virus inhibitors.

Method used

This invention provides 2-substituted acetamidobenzamide derivatives and their preparation methods. By molecular docking with influenza virus RNA polymerase, the binding mode is verified, and a pharmaceutical composition is prepared for local or systemic administration to treat influenza-related diseases.

Benefits of technology

This study provides a novel inhibitor with broad therapeutic effects against influenza viruses. It exhibits high stability, a simple preparation method, and stable yield, and can effectively treat influenza-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117903056B_ABST
    Figure CN117903056B_ABST
Patent Text Reader

Abstract

This invention discloses a 2-substituted acetamipridoxine derivative and its application in the preparation of anti-influenza virus drugs, belonging to the field of pharmaceutical technology. Specifically, it is a 2-substituted acetamipridoxine derivative or a pharmaceutically acceptable salt thereof with the structural formula shown in Formula I, wherein R1 and R2 are independently selected from hydrogen, cyclohexyl, methyl-substituted phenyl, chloro-substituted phenyl, or a thiomorpholino group together with the attached nitrogen atom. The 2-substituted acetamipridoxine derivative or a pharmaceutically acceptable salt thereof can be used in combination with existing drugs or alone as an influenza virus inhibitor, and has good efficacy against various types of influenza.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a 2-substituted acetamidobenzamide derivative and its application in the preparation of anti-influenza virus drugs. Background Technology

[0002] Influenza viruses are a class of pathogens that primarily infect the respiratory tracts of humans and animals. Humans infected with influenza viruses experience a range of symptoms, such as cough, headache, and fever. In children, the elderly, individuals with weakened immune systems, cancer patients, and those with chronic diseases such as diabetes and heart disease, the progression of influenza-induced disease can be rapidly aggravated (Schauwvlieghe A, Rijnders B, Philips N, et al. Invasive aspergillosis inpatients admitted to the intensive care unit with severe influenza: a spectral cohort study. Lancet respiratory medicine, 2018, 6(10):782-792.). According to the World Health Organization, approximately 99,000 to 200,000 people die from influenza each year (Hu W, Gtuner WE, Demarcus LS. Influenza surveillance trends and influenza vaccine effectiveness among department of defense beneficiaries during the 2019-2020 influenza season. MSMR, 2021, 28(3):2-8.). Currently, the most effective strategies for treating influenza are vaccines and small molecule anti-influenza drugs.

[0003] There are three main types of anti-influenza drugs currently on the market: M2 protein inhibitors, neuraminidase inhibitors, and RNA polymerase inhibitors. However, the proportion of drug-resistant viral strains is on the rise (Poland G, Jacobson R, Ovsyannikova I. Influenza virus resistance to antiviral agents: a plea for rational use. Clinical Infectious Diseases an Official Publication of the Infectious Diseases Society of America, 2009, 48(9): 1254-1256.). Therefore, the development of new anti-influenza virus drugs is urgently needed.

[0004] RNA-dependent RNA polymerase (RdRP) is a promising target, crucial for influenza virus transcription and replication (Shankaran S, Bearman GML. Influenzavirus resistance to neuraminidase inhibitors: Implications for treatment. Current infectious disease reports, 2012, 14(2):155-160.). The RdRP structure is highly conserved across all influenza virus strains and exhibits high host and cell specificity, making it less prone to drug resistance issues compared to M2 ion channel proteins and neuraminidase. Therefore, seeking inhibitors targeting influenza virus RNA polymerase has potential advantages. The discovery of 2-substituted acetamidobenzamide derivatives as influenza virus inhibitors is significant for expanding the influenza virus inhibitor molecule library and for the research of novel influenza virus inhibitors. Summary of the Invention

[0005] The technical problem solved by the present invention is to provide a 2-substituted acetamidobenzamide derivative, its preparation method and its application, specifically a 2-substituted acetamidobenzamide derivative as shown in Formula I or a pharmaceutically acceptable salt thereof, and to provide the application of said compound in the preparation of medicaments for treating influenza-related diseases.

[0006] 2-substituted acetamidobenzamide derivatives or pharmaceutically acceptable salts thereof, as shown in Formula I:

[0007]

[0008] in,

[0009] R1 and R2 are independently selected from hydrogen, cyclohexyl, methyl-substituted phenyl, chloro-substituted phenyl, or together with the attached nitrogen atom to form a thiomorpholino group.

[0010] Furthermore, R1 and R2 are independently selected from hydrogen, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, cyclohexyl, 4-chlorophenyl, or together with the attached nitrogen atom to form a thiomorpholino group.

[0011] Furthermore, the 2-substituted acetamidobenzamide derivative is any one of the following compounds:

[0012] 2-[2-(2-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0013] 2-[2-(4-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0014] 2-[2-(3-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0015] 2-[2-(cyclohexylamino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0016] 2-[2-(thiomorpholino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0017] 2-[2-(4-chloroanilino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide.

[0018] The present invention also provides a pharmaceutical composition comprising a 2-substituted acetamidobenzamide derivative as shown in Formula I and a pharmaceutically acceptable carrier or diluent.

[0019] This pharmaceutical composition is used to prepare a drug for treating influenza virus diseases. For example, using an aqueous saline solution as a carrier with a pH of 7.4, the pharmaceutical composition can be introduced into the patient's bloodstream in solution form via local injection.

[0020] The compounds of the present invention can be administered alone or in combination with pharmaceutically acceptable excipients such as carriers or diluents, in the form of a pharmaceutical composition, in accordance with conventional pharmaceutical practices. Routes of administration include oral administration or non-gastrointestinal routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal, and local routes.

[0021] For oral administration, in addition to tablets or capsules, it can also be administered in aqueous solution or suspension form. When administered orally, the active pharmaceutical ingredient is combined with an orally viable, non-toxic, pharmaceutically acceptable inert carrier to form a pharmaceutical composition. For oral administration in tablet or capsule form, carriers include lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, and sorbitol; for oral administration in liquid form, carriers include ethanol, glycerin, water, and combinations thereof. Furthermore, pharmaceutically acceptable binders, lubricants, disintegrants, and colorants may be added to the pharmaceutical composition. Binders include starch, gelatin, natural sugars such as glucose or lactose, corn sweeteners, natural and synthetic gums such as gum arabic, tragacanth, or sodium alginate, carboxymethyl cellulose, polyethylene glycol, and waxes. Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride. When an aqueous suspension is administered orally, the active ingredient is combined with an emulsifier and a suspending agent. Sweeteners or flavoring agents may also be added. For intramuscular, intraperitoneal, subcutaneous, and intravenous use, a sterile solution of the active ingredient is usually prepared, and the pH of the solution should be appropriately adjusted and buffered. For intravenous use, the total concentration of the solute should be controlled to maintain the isotonicity of the formulation.

[0022] The 2-substituted acetamidobenzamide derivatives of the present invention can also be used in combination with known pharmaceutical agents used to treat or prevent influenza. Preferred combinations include compounds of the present invention and M2 ion channel protein inhibitors, compounds of the present invention and neuraminidase inhibitors, compounds of the present invention and interferon inducers, compounds of the present invention and antisense oligonucleotides, and compounds of the present invention and inosine monophosphate dehydrogenase inhibitors.

[0023] The term "administer" and its variations (e.g., "administer" of a compound) in relation to this invention means the introduction of a 2-substituted acetamipridinamide derivative or a prodrug of that compound into an animal system requiring treatment. When a 2-substituted acetamipridinamide derivative or its prodrug is provided in combination with one or more other active agents, "administer" and its variations can be understood to include the simultaneous and sequential introduction of a 2-substituted acetamipridinamide derivative or its prodrug, along with other agents. Typically, the prodrug is a functional derivative of a 2-substituted acetamipridinamide derivative that readily converts in vivo to the desired compound. In this invention, the term "administer" will encompass a specifically disclosed 2-substituted acetamipridinamide derivative or a compound that may not be specifically disclosed but is convertible in vivo to the specific compound upon administration to a patient.

[0024] When the compounds of the present invention are administered to human subjects, the daily dose will generally be determined by the prescribing physician, and the dose will generally vary according to the individual patient's age, weight, response, and the severity of the patient's symptoms. In one exemplary application, an appropriate amount of the compound is administered to the treated mammal. When used for the indicated effects, the oral dose of the present invention will be from about 0.01 mg / kg body weight per day (mg / kg / day) to about 100 mg / kg / day, preferably from 0.01 mg / kg / day to 10 mg / kg / day, and most preferably from 0.1 mg / kg / day to 5.0 mg / kg / day. For oral administration, the composition is preferably provided in tablet form, wherein the tablets contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, and 500 mg of the active ingredient, preferably from 1 mg to 100 mg of the active ingredient. For intravenous injection, the most preferred dose during constant-rate infusion is 0.1 mg / kg / min to 10 mg / kg / min. The compounds of the present invention or pharmaceutical compositions comprising such compounds can be administered as a once-daily dose, or the total daily dose can be divided into two, three, or four daily doses. For administration via a transdermal drug delivery system, the dosage will naturally be continuous rather than intermittent throughout the dosing regimen.

[0025] Dosing regimens using the compounds of this invention will be selected based on a variety of factors, including patient type, species, age, weight, sex, and medical condition; severity of the condition being treated; route of administration; patient's renal and hepatic function; and the specific compound or its salt used. General technicians, veterinarians, or clinicians can readily determine and prescribe effective doses for prevention, treatment, or prevention of condition progression.

[0026] In the method of the present invention, the compounds described in detail herein can form an active ingredient and, depending on the form of administration, such as oral tablets, capsules, elixirs, syrups, etc., are mixed with a suitable pharmaceutically selected diluent, excipient, or carrier (collectively referred to herein as a “carrier” substance), in accordance with conventional pharmaceutical practices.

[0027] Pharmaceutically acceptable salts of the compounds of this invention refer to conventional acid addition salts or base addition salts formed by the combination of a suitable nontoxic organic acid or inorganic acid or organic base or inorganic base, which retain the biopotency and properties of the compound of formula I. Acid addition salts include hydrochlorides, hydrobroms, hydroiodates, nitrates, phosphates, sulfates, perchlorates, thiocyanates, hydrogen sulfates, persulfates, borates, formates, acetates, propionates, valerates, neovalerates, hexanoates, heptanoates, octanoates, isooctanoates, undecanoates, laurates, palmitates, stearates, oleates, cyclopropionates, oxalates, malonates, succinates, maleates, fumarates, adipates, azelaates, acrylates, strawberry salts, crotonates, tigrinates, itacrates, sorbates, cinnamates, glycolates, lactates, malates, tartrates, citrates, tartrites, mandelates, diphenylglycolates, tropine, ascorbate, gluconate, glucono-p-ethyl, gluconate, mannitol, lactobionate, benzoates, phthalates, paraphthalates, furoate, nicotinic acid, and isonicotinic acid. Salicylate, acetylsalicylate, butyrate, gallate, caffeate, ferulic acid, picrate, camphorate, camphor sulfonate, methanesulfonate, ethanesulfonate, propanesulfonate, benzenesulfonate, p-toluenesulfonate, p-aminobenzenesulfonate, aminosulfonate, taurine, 2-hydroxyethanesulfonate, glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartate, asparagine, glutamate, lysine, glutamine, methionine, serine, threonine, cysteine, proline, histidine, arginine, edetate, pyruvate, α-ketoglutarate, alginate, cyclopentanepropionate, 3-phenylpropionate, 3-cyclohexylpropionic acid, 2-naphthylcarboxate, 2-naphthylsulfonate, dihydroxynaphthylate, lauryl sulfate, glycerol phosphate, lauryl sulfate, pectin esters, etc. Base addition salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts of organic bases such as dicyclohexylamine salts and N-methyl-D-glucosamine salts. Furthermore, basic nitrogen-containing groups can be quaternized with reagents such as lower alkyl halides, such as chloro, bromine, and iodides of methyl, ethyl, propyl, and butyl groups; dialkyl sulfate esters, such as dimethyl, diethyl, dibutyl, and dipentyl sulfate; long-chain halides, such as chloro, bromine, and iodides of decyl, lauryl, myristyl, and stearoyl groups; and aralkyl halides, such as bromides of benzyl and phenethyl groups.

[0028] The present invention also provides a method for preparing the 2-substituted acetamidobenzamide derivative of general formula I, comprising the following steps:

[0029]

[0030] The interaction mode between the target compound and influenza virus RNA polymerase was preliminarily verified through molecular docking of the target compound and influenza virus RNA polymerase. In 2008, Obayashi et al. reported the crystal structure of influenza virus RNA polymerase (PDB ID: 2ZNL) (Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, Tame JR, Park SY. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature, 2008, 454: 1127-1131). Now, the binding mode of the target compound JJ06 with influenza virus RNA polymerase (PDB ID: 2ZNL) was predicted through molecular docking. Figure 1 The results showed that the indazole ring was embedded inside the cavity of the polymerase acidic (PA) fragment. The NH at the 1-position of the indazole ring formed a hydrogen bond with the amino acid residue ASN703. The indazole ring also had π-π interactions with the amino acid residues PHE707 and PHE658. The oxygen atom on the benzamide fragment formed a hydrogen bond with the amino acid residue LYS643. The benzene ring in the benzamide fragment had a π-π interaction with the amino acid residue TRP706. The terminal benzene ring of the side chain had a π-π interaction with the amino acid residues HIS713 and VAL628. The methyl group on the terminal benzene ring had a σ-π interaction with the amino acid PRO620.

[0031] In summary, researching inhibitors targeting influenza virus RNA polymerase has potential advantages. The discovery of 2-substituted acetamidobenzamide derivatives as influenza virus inhibitors is of great significance for expanding the influenza virus inhibitor molecular library and for the research of novel influenza virus inhibitors.

[0032] The beneficial effects of this invention are:

[0033] The compounds provided by this invention are novel influenza virus inhibitors that act on RNA polymerase, used to inhibit influenza viruses. Compared with currently marketed antiviral drugs that target other targets, influenza virus inhibitors acting on RNA polymerase are more stable. These influenza virus inhibitor compounds have broad therapeutic effects against influenza. Furthermore, the preparation method of these compounds is simple, yields are stable, and the prepared compounds can effectively treat influenza-related diseases. Attached Figure Description

[0034] Figure 1This is a schematic diagram of the binding pattern of compound JJ06 with the PA portion (PDB:2ZNL) of influenza virus RNA polymerase crystal. Detailed Implementation

[0035] The technical solution of the present invention will be described in detail below with reference to the specific embodiments. However, it should be understood that the present invention is not limited to the specific examples described below.

[0036] Example 1: Preparation of 2-[2-(2-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ01)

[0037] Step A: Preparation of methyl 2-(2-chloroacetamido)benzoate

[0038] 15.12 g (0.10 mol) of methyl anthranilate, 60 mL of dichloromethane, and 18.00 g (0.13 mol) of potassium carbonate were added to a 250 mL round-bottom flask. 11.20 g (0.10 mol) of chloroacetyl chloride was diluted in 50 mL of dichloromethane and added dropwise to the round-bottom flask under ice bath conditions. After the addition was complete, the reaction was carried out at room temperature for 1 h. The reaction mixture was monitored by thin-layer chromatography (TLC) to ensure complete reaction. The reaction solution was transferred to 100 mL of water to dissolve the remaining potassium carbonate, and the organic phase was separated. The aqueous phase was extracted twice with 20 mL of dichloromethane. The organic phases were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give 20.51 g of white solid (yield 90.10%); mp: 122.1-123.5℃; ESI-MS m / z: 228.1 ([M+H]). + ).

[0039] Step B: Preparation of 2-[2-(2-methylaniline)acetamido]benzoic acid

[0040] 2.00 g (8.80 mmol) of methyl 2-(2-chloroacetamido)benzoate, 3.65 g (26.40 mmol) of potassium carbonate, 10.56 mmol of o-toluidine, 0.33 g (2.00 mmol) of potassium iodide, and 70 mL of tetrahydrofuran were added to a 100 mL round-bottom flask and reacted at 68 °C. The reaction was monitored by TLC until the reactants were completely reacted (24 h). The potassium carbonate was filtered off, the filtrate was collected, and the solvent was evaporated under reduced pressure to obtain a viscous solid. The solid was then slurried with petroleum ether, filtered, and the residue was washed with water to obtain 2.63 g of a white solid.

[0041] 2.63 g (8.81 mmol) of the product obtained in the previous step, 3.65 g (26.43 mmol) of potassium hydroxide, 10 mL of water, and 30 mL of ethanol were added to a 100 mL round-bottom flask. The reaction was carried out at 78 °C, and the reaction was monitored by TLC until the reaction was complete (3 h). The ethanol was removed under reduced pressure, and the pH was adjusted to about 6 with glacial acetic acid, resulting in the precipitation of a large amount of solid. The solid was filtered to give 1.80 g of white solid, yield 72.0%; mp: 265.1-266.2 °C; ESI-MS m / z: 285.1 ([M+H]). + ).

[0042] Step C: Preparation of 2-[2-(2-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide

[0043]

[0044] 0.85 g (3.00 mmol) of 2-[2-(2-methylaniline)acetamido]benzoic acid, 1.4 g (3.60 mmol) of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU), and 30 mL of N,N-dimethylformamide (DMF) were added to a 50 mL round-bottom flask. After reacting at room temperature for 1 hour, 0.53 g (3.60 mmol) of 1H-indazole-7-methylamine and 0.58 g (4.50 mmol) of N,N-diisopropylethylamine (DIPEA) were added, and the reaction was continued at room temperature. The reaction mixture was monitored by TLC until the starting material was completely reacted (24 h). The reaction solution was poured into 100 mL of water, extracted with 10 mL of ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain the crude product. Column chromatography yielded 0.15 g of a white solid, with a yield of 76.5%. mp: 246.6-247.0℃; 1 H NMR (400MHz, DMSO-d6) δ13.06 (s, 1H), 11.83 (s, 1H), 9.17 (t, J = 5.7Hz, 1H), 8.63-8.48 ( m,1H),8.12(s,1H),7.80-7.71(m,1H),7.71-7.66(m,1H),7.55-7.43(m,1H),7.15-7.1 2(m,2H),7.08-7.04(m,1H),6.99-6.94(m,2H),6.55(t,J=7.3Hz,1H),6.36-6.34(m,1H ),5.79-5.76(m,1H),4.65(d,J=5.7Hz,2H),3.86(d,J=5.6Hz,2H),2.21(s,3H); ESI-MS m / z:414.5([M+H] + ).

[0045] Example 2: Preparation of 2-[2-(4-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ02)

[0046]

[0047] Following the preparation method of Example 1, 0.13 g of a white solid was obtained, with a yield of 74.5%. mp: 188.0-189.0 °C; 1 H-NMR (400MHz, DMSO-d6); δ13.09 (s, 1H), 11.72 (s, 1H), 9.19 (t, J = 5.5Hz, 1H), 8.54-8. 52(m,1H),8.12(s,1H),7.78-7.76(m,1H),7.68-7.66(m,1H),7.51-7.49(m,1H),7.17- 7.14(m,2H),7.07-7.04(m,1H),7.07-7.04(m,2H),6.90-6.88(m,2H),6.50-6.48(m,2H ),6.20-6.17(m,1H),4.67(d,J=5.5Hz,2H),3.75(d,J=5.6Hz,2H),2.12(s,3H); ESI-MS m / z:414.2([M+H] + ).

[0048] Example 3: Preparation of 2-[2-(3-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ03)

[0049] Following the preparation method of Example 1, 0.12 g of a white solid was obtained, with a yield of 74.8%. mp: 212.1-213.0 °C; 1 H-NMR (400MHz, DMSO-d6); δ13.08 (s, 1H), 11.70 (s, 1H), 9.21 (t, J = 5.8Hz, 1H) ,8.54-8.52(m,1H),8.12(s,1H),7.77-7.76(m,1H),7.53-7.49(m,1H),7.18- 7.16(m,2H),7.10-7.02(m,1H),6.99-6.97(m,1H),6.48-6.34(m,3H),6.28-6 .26(m,1H),4.68(d,J=5.8Hz,2H),3.77(d,J=5.7Hz,2H),2.16(s,3H); ESI-MS m / z:414.2([M+H] + ).

[0050] Example 4: Preparation of 2-[2-(cyclohexylamino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ04)

[0051]

[0052] Following the preparation method of Example 1, 0.16 g of a white solid was obtained, with a yield of 76.8%. mp: 181.7-182.2℃; 1 H-NMR (400MHz, DMSO-d6); δ13.08(s,1H),11.76(s,1H),9.22(t,J=5.8Hz,1H),8.52-8.50(m,1H),8.12(s,1H),7.75-7.73(m,1H),7. 69-7.67(m,1H),7.49-7.47(m,1H),7.26-7.25(m,1H),7.16-7.14(m,1H),7.12-7.06(m,1H),4.79(d,J=5.8Hz,2H),3.27(d,J=5.7Hz 2H),2.31(s,1H),1.82-1.79(m,2H),1.61-1.58(m,2H),1.48-1.45(m,1H),1.07-0.99(m,6H); ESI-MS m / z:406.2([M+H] + ).

[0053] Example 5: Preparation of 2-[2-(thiomorpholino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ05)

[0054]

[0055] Following the preparation method of Example 1, 0.18 g of a white solid was obtained, with a yield of 78.2%. mp: 184.2-185.0 °C; 1H-NMR (400MHz, DMSO-d6); δ13.14(s,1H),11.70(s,1H),9.27(t,J=5.8Hz,1H), 8.51-8.49(m,1H),8.12(s,1H),7.82-7.74(m,1H),7.68-7.66(m,1H),7.55-7. 46(m,1H),7.25-7.24(m,1H),7.21-7.15(m,1H),7.13-7.06(m,1H),4.80(d,J= 5.8Hz,2H),3.09(d,J=5.7Hz,2H),2.72-2.63(m,4H),2.62-2.54(m,4H); ESI-MS m / z: 410.2([M+H] + ).

[0056] Example 6: Preparation of 2-[2-(4-chloroanilino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide (JJ06)

[0057]

[0058] Following the preparation method of Example 1, 0.13 g of a white solid was obtained, with a yield of 72.8%. mp: 165.1-166.50 °C; 1 H-NMR (400MHz, DMSO-d6); δ13.09(s,1H),11.73(s,1H),9.20(t,J=5.7Hz,1H),8.53-8.51(m,1H),8.12(s,1H),7.79-7.77(m,1H) ,7.68-7.66(m,1H),7.52-7.51(m,1H),7.19-7.05(m,5H),6.59-6.57(m,3H),4.67(d,J=5.7Hz,2H),3.81(d,J=5.6Hz,2H); ESI-MS m / z:434.1([M+H] + ).

[0059] Example 7: Toxicity of the target compound

[0060] The MTT assay based on Madin-Daby canine kidney cells (MDCK) was used to test the cytotoxicity of target compounds JJ01–JJ06 at the cellular level. Different concentrations of the target compounds were added to the MDCK cell culture medium, and the absorbance (OD) values ​​were read using an enzyme-linked immunosorbent assay (ELISA) analyzer. The survival rate of MDCK cells was calculated (MDCK cell survival rate = absorbance value of experimental group / absorbance value of blank control group). The results are shown in Table 1. A lower MDCK cell survival rate indicates a stronger inhibitory effect of the target compound on MDCK cell growth, and thus greater cytotoxicity.

[0061] Table 1. Inhibitory effect of the target compound on MDCK cells

[0062]

[0063] Compound JJ06 at a concentration of 100 μmol·L -1 50 μmol·L -1 25 μmol·L -1 12.5 μmol·L -1 The survival rates of MDCK cells were 0.5277, 0.5193, 0.5103, and 0.5540, respectively, and the growth inhibition rates of the compounds were 47.23%, 48.07%, 48.97%, and 44.60%, respectively (inhibition rate of the compound on cells = (absorbance value of the control group - absorbance value of the experimental group) / absorbance value of the control group * 100%). JJ06 showed a strong inhibitory effect on MDCK cells, thus exhibiting certain cytotoxicity. The inhibitory ability of the other compounds on MDCK cells was not as significant as that of JJ06.

[0064] Example 8: Protective effect of the compound on diseased cells

[0065] The MTT assay was used to investigate the protective effect of the target compound on influenza virus-infected cells. Different concentrations of the target compound were added to the culture medium of the infected cells, and the absorbance (OD) values ​​were read using an enzyme-linked immunosorbent assay (ELISA) analyzer. The cell viability was calculated (cell viability = absorbance value of the experimental group / absorbance value of the virus-free control group). The results are shown in Table 2. A higher cell viability indicates a stronger protective ability of the target compound against the cells and a stronger inhibitory activity against the influenza virus.

[0066] Table 2. Protective effect of the target compound on diseased cells.

[0067]

[0068] Experimental results showed that JJ06 exhibited better protective activity against diseased cells compared to other compounds at a concentration of 12.5 μmol·L⁻¹. -1 25 μmol·L -1 50 μmol·L -1 100 μmol·L -1 Under these conditions, the survival rates of the diseased cells were 17.27%, 21.70%, 20.83%, and 21.53%, respectively.

[0069] Based on the results of the cytotoxicity and disease cell protection experiments of the target compound above, it can be seen that:

[0070] (1) The structural differences of the target compounds lie in the terminal substituents: there is no significant difference in the activity of compounds JJ01, JJ02, and JJ03, indicating that the position of the methyl group on the terminal benzene ring does not significantly affect the activity; when the terminal is substituted with an aromatic ring, compound JJ02 has a stronger protective ability against diseased cells than compounds JJ04 and JJ05, which are substituted with an aliphatic ring at the end, indicating that the activity of the terminal substituted benzene ring is better than that of the aliphatic ring.

[0071] (2) Compound JJ06 has the strongest protective ability against diseased cells. Compared with other compounds, it is also slightly more toxic to normal cells, indicating that the protective ability of introducing a halogen group on the terminal benzene ring is better than that of introducing an alkyl group on the terminal ring.

[0072] In the formulations described below, "active ingredient" refers to the compound represented by Formula I, or its salt or solvate.

[0073] Example 9: Gelatin Capsules

[0074]

[0075] Example 10: Tablets

[0076]

[0077] Example 11: Tablets

[0078]

[0079]

[0080] The active ingredient, starch, and cellulose are thoroughly mixed through a 45-mesh US sieve. The resulting powder is then mixed with polyvinylpyrrolidone and passed through a 14-mesh US sieve. The resulting granules are dried at 50-60°C and passed through an 18-mesh US sieve. Sodium carboxymethyl cellulose, magnesium stearate, and talc are first passed through a 60-mesh US sieve and then added to the granules. After mixing, the mixture is compressed into tablets using a tableting machine.

[0081] Example 12: Suspension

[0082]

[0083] The drug is passed through a 45-mesh US sieve and mixed with sodium carboxymethyl cellulose and syrup to form a uniform paste. Benzoic acid solution, flavoring agent and coloring agent are diluted with some water and added while stirring. Then, enough water is added to reach the desired volume.

[0084] Example 13: Aerosol

[0085]

[0086] The active ingredient is mixed with ethanol, and the resulting mixture is added to propellant 22, cooled to 30°C, and transferred to a container. The required amount is then added to a stainless steel container and diluted with the remaining propellant before installing the valve device.

[0087] Example 14: Suppositories

[0088]

[0089] The active ingredient was passed through a 60-mesh US sieve and suspended in a pre-melted saturated fatty acid glyceride compound. The mixture was then poured into a standard 2g suppository mold and cooled.

[0090] Example 15: Injectable Formulation

[0091]

[0092] The above solution is administered intravenously to the patient at a rate of approximately 1 mL / min.

[0093] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any other way. Any person skilled in the art may make changes or modifications to the above-disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the protection scope of the present invention.

Claims

1. A 2-substituted acetamidobenzamide derivative with the structural formula shown in Formula I, or a pharmaceutically acceptable salt thereof: in, R1 and R2 are independently selected from hydrogen, cyclohexyl, methyl-substituted phenyl, chloro-substituted phenyl, or together with the attached nitrogen atom to form a thiomorpholino group.

2. The 2-substituted acetamidobenzamide derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that, In Formula I, R1 and R2 are independently selected from hydrogen, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, cyclohexyl, 4-chlorophenyl, or thiomorpholinoyl along with the attached nitrogen atom.

3. The 2-substituted acetamidobenzamide derivative or a pharmaceutically acceptable salt thereof according to claim 2, characterized in that, The 2-substituted acetamidobenzamide derivatives are selected from the following compounds: 2-[2-(2-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide 2-[2-(4-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide 2-[2-(3-methylaniline)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide 2-[2-(cyclohexylamino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide 2-[2-(thiomorpholino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide 2-[2-(4-chloroanilino)acetamido]-N-[(1H-indazol-7-yl)methyl]benzamide.

4. The method for preparing the 2-substituted acetamidobenzamide derivative compound according to claim 1, characterized in that, Includes the following steps:

5. A pharmaceutical composition, characterized in that, The active ingredient includes any one of the 2-substituted acetamidobenzamide derivatives or pharmaceutically acceptable salts thereof as claimed in any one of claims 1-3, and a pharmaceutically acceptable carrier or diluent.

6. Use of the 2-substituted acetamidobenzamide derivative or a pharmaceutically acceptable salt thereof as described in any one of claims 1-3 in the preparation of an influenza virus therapeutic.

7. The use of the pharmaceutical composition of claim 5 in the preparation of an influenza virus treatment drug.

8. The use of the 2-substituted acetamidobenzamide derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-3 in the preparation of a medicament for inhibiting influenza virus replication, characterized in that, The 2-substituted acetamidobenzamide derivative or a pharmaceutically acceptable salt thereof acts on the RNA polymerase of influenza virus to inhibit influenza virus replication.

9. The use of the pharmaceutical composition of claim 5 in the preparation of a medicament for inhibiting influenza virus replication, characterized in that, The pharmaceutical composition acts on the RNA polymerase of the influenza virus, inhibiting the replication of the influenza virus.

Citation Information

Patent Citations

  • Anthranilic acid derivative

    CN1118595A

  • Compounds for the treatment and prevention of retroviral infections

    US20150265557A1